Home » Newsletters » BioWorld Science

BioWorld Science

July 17, 2001

View Archived Issues

Novel chimeric protein with potential application as HIV therapy available for licensing from NIH

Licensing opportunity from NIH: beta2-microglobulin fusion proteins

Bayer and m-phasys collaborate on protein-targeting drug discovery tools

Preclinical pipeline at Faes includes new antidepressant and antipsychotic agents

Nerve injury-induced gene discovered by Washington University scientists

GlaxoSmithKline and Taisho collaborate on smoking control products

Antisoma enters supply agreement for thioplatin

Genentech highlights business and product events for Q2 2001

Liposome-mediated eNOS gene transfection for reducing myocardial ischemia-reperfusion injury

New England Journal of Medicine publishes pivotal data for Fabrazyme

Aventis licenses new solid tumor treatment from Ajinomoto

Significant clinical antileukemic activity demonstrated for signal transduction inhibitor

Antigenics finalizes acquisition of Aronex; broadens pipeline

Alpha1A-adrenoceptor blockade not associated with improvement in MED

Vion awarded SBIR grant to support development of sulfonyl hydrazine prodrugs

Vevesca enters U.S. trial for Gaucher's disease

Mozenavir vs. indinavir in antiretroviral-naive HIV patients

Pharmacia receives nonapprovable letter from FDA for analgesic product

Dynamics of anti-HIV response to GPG-NH2 examined after oral and s.c. dosing

Consensus granted NIH funding to support research on HIV entry inhibitors

Immunex advances IL-1 regulator to clinical trials

MedImmune evaluates Vitaxin in new clinical trial in colorectal cancer patients

Treatment of mild cognitive impairment with glucocorticoid receptor antagonists

Australian researchers identify new tumor suppressor gene

HIV protease inhibitors designed at Merck with improved activity against HIV mutants

Preparation and use of CSBP/p38 kinase inhibitors in respiratory and other inflammatory disorders

Sepracor preparing for NDA submission of insomnia drug candidate

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 10, 2026.
Cas and effect: Merck’s phase III ripples HIF-2α space
BioWorld
Oddsmakers wasted no time figuring the market chances after Merck & Co. Inc. rolled out data from the phase III Litespark-011 study testing its oral...
Brain’s hidden tau-clearing pathway uncovered
BioWorld Science
Researchers at INSERM and collaborators have identified hypothalamic tanycytes as mediators of tau clearance and shown that their structural and genetic...
News in brief
BioWorld Asia
BioWorld Asia briefs for March 10, 2026
MSD synthesizes α-synuclein PET agents
BioWorld Science
Merck Sharp & Dohme LLC (MSD) has prepared and tested new positron emission tomography (PET) agents for binding and imaging α-synuclein (SNCA) for the diagnosis...